MP-0317 is under clinical development by Molecular Partners and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MP-0317’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MP-0317 is under development for the treatment of colorectal cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, cervical cancer, anal cancer, melanoma, pancreatic cancer, gastric cancer, endometrial cancer, urothelial/bladder cancer, head and neck squamous cell carcinoma, breast cancer, mesothelioma and cutaneous squamous cell carcinoma. The therapeutic candidate is a bi-specific protein that acts by targeting CD40 and fibroblast activating protein (FAP) which is expressed in stroma of many tumor cells. It is administered by intravenous route and developed based on designed ankyrin repeat proteins (DARPin) technology.
Molecular Partners overview
Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration. It also develops drugs on DARPin base technology and other product candidates. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications. The company also provides clinical trial services and small protein therapies called Darpin therapeutics. It has partnership with a pharmaceutical company to strengthen drug platforms through in-house development, licensing and collaboration. Molecular Partners is headquartered in Zurich, Switzerland.
For a complete picture of MP-0317’s drug-specific PTSR and LoA scores, buy the report here.